Sweden's Medivir Strengthens Executive Team, Aims To Become Profitable Specialty Firm
This article was originally published in The Pink Sheet Daily
Executive Summary
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.